ITCI Live signals | Maximize Profits with Getagraph.com

BUY 824 min ago

@ $73.20

Issued: 24 Apr 2024 @ 14:21

Return: -0.11%

Previous signal: Apr 24 - 12:43

Previous signal: Sell

Return: -0.46 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	713 985
Average Volume	973 385
Market Cap	7.08B
EPS	$0 ( 2024-02-22 )
Next earnings date	( $-0.330 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-50.08
ATR14	$1.695 (2.32%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-31	Van Nostrand Robert L	Buy	79	Common Stock
2024-03-31	Riggs Rory B	Buy	260	Common Stock
2024-03-20	Riggs Rory B	Buy	20 000	Common Stock
2024-03-20	Riggs Rory B	Sell	20 000	Stock Option (right to buy)
2024-03-10	Mates Sharon	Buy	20 565	Common Stock

INSIDER POWER
-0.65
Last 100 transactions
Buy: 514 872 \| Sell: 520 193

Volume Correlation

Long: -0.69 (moderate negative)

Short: -0.98 (very strong negative)

Signal:(47) Neutral

Intra-Cellular Therapies Correlation

10 Most Positive Correlations
BOCH	0.927
SHSP	0.882
BLRX	0.862
SOVO	0.851
DBDR	0.84
MMAC	0.838
GWAC	0.833
SCYX	0.825
FCAC	0.823
TLSA	0.823

10 Most Negative Correlations
GAINL	-0.944
APOP	-0.87
RMRM	-0.867
TDAC	-0.855
ISNS	-0.852
FNWD	-0.85
CLDX	-0.836
MNDO	-0.835
SVOK	-0.835
AGIL	-0.83

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Intra-Cellular Therapies Correlation - Currency/Commodity

0.38
( neutral )

0.36
( neutral )

0.00
( neutral )

0.33
( neutral )

0.18
( neutral )

-0.46
( neutral )

Intra-Cellular Therapies Financials

Annual	2023
Revenue:	$462.18M
Gross Profit:	$428.43M (92.70 %)
EPS:	$-1.460

Q4	2023
Revenue:	$131.51M
Gross Profit:	$120.80M (91.86 %)
EPS:	$-0.300

Q3	2023
Revenue:	$125.81M
Gross Profit:	$116.68M (92.74 %)
EPS:	$-0.250

Q2	2023
Revenue:	$110.13M
Gross Profit:	$102.97M (93.50 %)
EPS:	$-0.450

Financial Reports:

No articles found.

Intra-Cellular Therapies

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.